VBL Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference
March 15, 2017 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, March 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics to Present at the 29th Annual ROTH Conference
March 07, 2017 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, March 07, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics to Report Full-Year 2016 Financial Results on March 27
March 02, 2017 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, March 02, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Reports Full Data for VB-111 Monotherapy in Phase 2 Trial for Recurrent Thyroid Cancer
February 21, 2017 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Feb. 21, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today full results from its exploratory Phase 2 study of VB-111 (ofranergene obadenovec) in patients...
VBL Therapeutics to Present at the 2017 BIO CEO & Investor Conference
February 06, 2017 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Feb. 06, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Announces Publication of Research on a Potential Novel Immuno-Oncology Target
January 31, 2017 16:01 ET
|
VBL Therapeutics
TEL AVIV, Israel, Jan. 31, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today the publication of a paper discussing MOSPD2, a potential novel immuno-oncology target. The paper,...
VBL Therapeutics Provides Year End 2016 Corporate Update
January 09, 2017 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Jan. 09, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), provides corporate update and reviews anticipated highlights for 2017. Following positive EOP2 meeting on VB-111...
VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE Study
January 06, 2017 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Jan. 06, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today that it has completed enrollment in the GLOBE Phase 3 study evaluating the efficacy of its lead...
VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM
December 05, 2016 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Dec. 05, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced that the independent Data Safety Monitoring Committee (DSMC) met to conduct its first safety...
VBL Therapeutics Announces Overall Survival Data for VB-111 Monotherapy in Phase 2 Study for Recurrent Thyroid Cancer
November 29, 2016 07:00 ET
|
VBL Therapeutics
The study met its primary endpoint, demonstrating disease stabilization and safety, along with a dose-responseNewly released data show evidence of an overall survival benefit for patients treated with...